Please ensure Javascript is enabled for purposes of website accessibility

Why Spark Therapeutics Stock Soared 137% in February

By Demitri Kalogeropoulos - Updated Apr 11, 2019 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company agreed to be purchased at a hefty premium.

What happened

Spark Therapeutics (ONCE) stock outpaced the market by a wide margin last month, gaining 137% compared to a 3% spike in the S&P 500, according to data provided by S&P Global Market Intelligence.

The increase put shareholders back in significantly positive territory, with returns of over 70% in the past year versus a 3% increase in the broader market.

Scientists performing clinical research.

Image source: Getty Images.

So what

Last month's rally came as a result of the biotech company announcing an agreement to be purchased by Roche Holdings (RHHBY 0.79%) for nearly $5 billion, or $114.50 per share. That price equates to a 122% premium over the stock's value on trading day prior to the deal's announcement.

Check out the latest earnings call transcript for Spark.

Now what

Spark Therapeutics shareholders should see their stock holdings convert to cash at that $114.50 price when the deal closes sometime in the second quarter of 2019. After that, the company will continue to operate as an independent group within Roche Holdings, but will benefit from its parent's global reach as it seeks to better commercialize treatments like its Luxturna genetic eye disease drug. That deal ensures positive returns for all shareholders, which counts as a solid win in the volatile biotech world.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Spark Therapeutics Stock Quote
Spark Therapeutics
Roche Holding AG Stock Quote
Roche Holding AG
$43.33 (0.79%) $0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.